| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | GlycoMimetics GAAP EPS of -$0.17 in-line | 12 | Seeking Alpha | ||
| Do | GLYCOMIMETICS INC - 10-Q, Quarterly Report | 4 | SEC Filings | ||
| 06.05. | GlycoMimetics hits record low as blood cancer drug fails in late-stage study | 21 | Reuters | ||
| 06.05. | GlycoMimetics' Uproleselan Flunks In Late Stage Leukemia Study, Shares Sink | 11 | Benzinga.com | ||
| 06.05. | Why Is GlycoMimetics (GLYC) Stock Down 77% Today? | 12 | InvestorPlace | ||
| 06.05. | GlycoMimetics plummets 77% as phase 3 leukemia therapy uproleselan fails | 9 | Seeking Alpha | ||
| 06.05. | GlycoMimetics fails phase 3 blood cancer trial, causing investors to sour on stock | 7 | FierceBiotech | ||
| 06.05. | GlycoMimetics falls as blood cancer drug fails in late-stage study | 9 | Reuters | ||
| 06.05. | Why Is GlycoMimetics Stock Falling In Pre-market? | 11 | RTTNews | ||
| 06.05. | GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) | 124 | Business Wire | ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory... ► Artikel lesen | |
| 02.05. | GLYCOMIMETICS INC - 8-K, Current Report | 7 | SEC Filings | ||
| 28.03. | GlycoMimetics, Inc. (GLYC) Q4 2023 Earnings Call Transcript | 6 | Insider Monkey | ||
| 27.03. | Earnings call: GlycoMimetics outlines Phase III trial progress and financials | 2 | Investing.com | ||
| 27.03. | GLYCOMIMETICS INC - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 27.03. | GlycoMimetics Inc reports results for the quarter ended in December - Earnings Summary | 3 | Reuters | ||
| 27.03. | GLYCOMIMETICS INC - 8-K, Current Report | 2 | SEC Filings | ||
| 27.03. | GLYCOMIMETICS INC - 10-K, Annual Report | 3 | SEC Filings | ||
| 27.03. | GlycoMimetics GAAP EPS of -$0.14 beats by $0.01 | 4 | Seeking Alpha | ||
| 27.03. | GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023 | 73 | Business Wire | ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory... ► Artikel lesen | |
| 26.03. | GlycoMimetics Q4 2023 Earnings Preview | 2 | Seeking Alpha |
Seite:
1 2 Weiter >>
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| EVOTEC | 5.300 |
| PLUG POWER | 4.005 |
| BAYER | 3.993 |
| TUI | 3.828 |
| NEL | 3.769 |
| GAMESTOP | 3.535 |
| RHEINMETALL | 2.564 |
| AMC ENTERTAINMENT | 2.365 |
| SIEMENS ENERGY | 1.973 |
| ALIBABA | 1.755 |
| MERCEDES-BENZ | 1.741 |
| NVIDIA | 1.720 |
| NOVAVAX | 1.605 |
| NORDEX | 1.601 |
| BYD | 1.444 |
| DEUTSCHE BANK | 1.330 |
| DELIVERY HERO | 1.289 |
| AIXTRON SE | 1.256 |
| VOLKSWAGEN | 1.202 |
| RWE | 1.152 |
| PALANTIR TECHNOLOGIES | 1.139 |
| TESLA | 1.138 |
| ALLIANZ | 1.097 |
| COMMERZBANK | 1.066 |
| K+S | 967 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
